Compare Moderna, Inc. (MRNA) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs SYSCO Corporation — how do they compare? Moderna, Inc. trades at $136.3 (market cap $54.14B), while SYSCO Corporation trades at $81.58 (market cap $39.08B). The key difference: Moderna, Inc. is the larger of the two by market cap, and SYSCO Corporation pays a 2.7% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SYY | |
|---|---|---|
Market Cap | $54.14B | $39.08B |
Sector | Health | Consumer Staples |
52-Week High | $174.38 | $91.16 |
52-Week Low | $22.36 | $69.30 |
Enterprise Value | $50.29B | $52.26B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Sysco Corporation (SYY) trades at $79.84, down 0.26% with a bullish technical signal despite mixed moving averages. The company reported $81.37B in revenue for 2025 with a 2.08% net margin and maintains strong analyst support with 60% buy ratings. Recent news highlights AI efficiency initiatives and reaffirmed 2027 guidance, while the pending Jetro Restaurant Depot acquisition presents both growth opportunities and integration risks.
Sysco offers stable fundamentals with consistent revenue growth and dividend aristocrat status, but faces execution risks from its major acquisition and margin pressures. The stock trades below the $88.25 consensus target, suggesting potential upside if AI efficiency gains materialize and integration proceeds smoothly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
